Ryvu Therapeutics S.A. (WSE:RVU)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	50.66	59.61	160.07	57.94	101.92	83.24
Short-Term Investments	24.08	48.07	65.86	175.73	0.53	4.99
Cash & Short-Term Investments	74.74	107.68	225.93	233.67	102.45	88.23
Cash Growth	418.68%	-52.34%	-3.31%	128.09%	16.11%	-45.26%
Accounts Receivable	7.27	10.6	15.66	9.19	1.05	5.94
Other Receivables	7	9.5	20.12	23.65	258.85	5.8
Receivables	14.27	20.1	35.78	32.84	259.89	11.74
Inventory	1.15	1.34	1.21	2.12	1.76	1.96
Prepaid Expenses	-	-	-	-	2.35	1.63
Other Current Assets	7.61	10.14	9.52	9.77	1.48	0.69
Total Current Assets	97.77	139.25	272.44	278.39	367.93	104.25
Property, Plant & Equipment	66.69	70.02	72.74	77.56	82.22	91.18
Long-Term Investments	6.67	6.38	16.77	34.37	20.48	29.4
Other Intangible Assets	6.2	6.04	8.12	6.34	4.28	3.04
Long-Term Deferred Tax Assets	-	-	-	-	-	0.33
Other Long-Term Assets	5.23	2.75	8.72	6.55	0.08	0.6
Total Assets	182.56	224.44	378.78	403.2	474.98	228.81

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	16.38	16.23	31.15	23.14	12.58	11.69
Accrued Expenses	3.92	3.74	12.28	12.22	11.7	4.86
Short-Term Debt	0.09	0.11	0.29	0.13	0.06	0.02
Current Portion of Long-Term Debt	8.67	16.08	25.79	-	0.81	0.81
Current Portion of Leases	0.33	0.38	0.5	0.41	1.03	1.92
Current Income Taxes Payable	-	-	-	-	-	5.46
Current Unearned Revenue	16.3	23.19	35.71	31.53	16.71	8.95
Other Current Liabilities	-	1.86	2.21	2.27	1.93	2.5
Total Current Liabilities	45.7	61.58	107.93	69.7	44.81	36.2
Long-Term Debt	82.22	78.38	74.15	8.85	9.9	8.86
Long-Term Leases	0.78	0.96	1.39	0.37	0.87	1.58
Long-Term Unearned Revenue	25.31	29.5	42.74	64.26	75.8	20.26
Pension & Post-Retirement Benefits	0.18	0.18	0.28	0.43	0.14	0.12
Long-Term Deferred Tax Liabilities	-	-	-	-	-	0.44
Other Long-Term Liabilities	-	-	-	-	0.06	0.06
Total Liabilities	154.19	170.6	226.48	143.61	131.59	67.51

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	9.25	9.25	9.25	9.25	7.34	7.34
Additional Paid-In Capital	519.75	519.75	519.75	519.75	279.06	279.06
Retained Earnings	-238.38	-212.67	-111.44	-0.01	92.1	175.88
Comprehensive Income & Other	-262.24	-262.49	-265.26	-269.39	-35.12	-300.99
Total Common Equity	28.37	53.83	152.29	259.59	343.39	161.3
Shareholders' Equity	28.37	53.83	152.29	259.59	343.39	161.3
Total Liabilities & Equity	182.56	224.44	378.78	403.2	474.98	228.81

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	92.09	95.9	102.12	9.76	12.67	13.19
Net Cash (Debt)	-17.35	11.78	123.81	223.91	89.77	75.04
Net Cash Growth	-	-90.49%	-44.71%	149.42%	19.63%	-51.20%
Net Cash Per Share	-0.75	0.51	5.36	9.78	4.89	4.09
Filing Date Shares Outstanding	23.12	23.12	23.12	23.12	23.12	18.36
Total Common Shares Outstanding	23.12	23.12	23.12	23.12	23.12	18.36
Working Capital	52.08	77.67	164.51	208.69	323.12	68.05
Book Value Per Share	1.23	2.33	6.59	11.23	14.85	8.79
Tangible Book Value	22.18	47.79	144.18	253.26	339.11	158.26
Tangible Book Value Per Share	0.96	2.07	6.24	10.95	14.67	8.62
Land	-	7.47	7.47	7.47	7.47	7.47
Buildings	-	52.28	52.21	52.2	52.15	53
Machinery	-	15.79	16.09	15.38	14.15	13.8
Construction In Progress	-	-	0.35	-	-	0.61

Data Source: S&P Global Market Intelligence Last updated: Sep 17, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 25, 2026

Data Sources Report a data error